Gilead Sciences Inc.
Equity & Debt
| Period | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| Mar 2022 | $25.18B | $19.93B | $4.30B |
| Jun 2022 | $25.20B | $20.24B | $4.74B |
| Sep 2022 | $22.95B | $21.08B | $4.70B |
| Dec 2022 | $22.96B | $21.24B | $5.41B |
| Mar 2023 | $22.96B | $21.00B | $4.94B |
| Jun 2023 | $21.21B | $21.16B | $5.70B |
| Sep 2023 | $23.19B | $22.31B | $5.71B |
| Dec 2023 | $23.19B | $22.83B | $6.09B |
| Mar 2024 | $21.53B | $17.54B | $4.72B |
| Jun 2024 | $21.54B | $18.28B | $2.77B |
| Sep 2024 | $21.44B | $18.48B | $5.04B |
| Dec 2024 | $24.90B | $19.33B | $9.99B |
| Mar 2025 | $22.15B | $19.16B | $7.93B |
| Jun 2025 | $22.14B | $19.67B | $5.14B |
| Sep 2025 | $22.14B | $21.54B | $7.33B |
| Dec 2025 | $22.13B | $22.70B | $7.56B |
| Mar 2026 | $20.86B | $23.52B | $7.63B |
| Jun 2026 | $23.83B | $11.83B | $3.18B |